Gyre Therapeutics (GYRE) Cash from Operations (2010 - 2026)
Gyre Therapeutics (GYRE) reported Cash from Operations of 3200000.0 for Q1 2026, up 2580.62% year-over-year from 119375.36 in Q1 2025, and up 157.14% on a QoQ basis from 5600000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Cash from Operations data on file, last reported at 3200000.0 in Q1 2026.
- Quarterly Cash from Operations rose 2580.62% year-over-year to 3200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4329000.0 (up 165.06% YoY) and the FY2025 annual result came in at 1000000.0, up 127.46% from the prior year.
- Cash from Operations climbed to 3200000.0 in Q1 2026 per GYRE's latest filing, from 5600000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 42298000.0 in Q4 2022 and bottomed at 12294000.0 in Q2 2022.
- The 5-year median for Cash from Operations is 2129000.0 (2025), against an average of 2184000.0.
- The widest annual swing landed in 2024, when Cash from Operations sank 221.18%; it then soared 2580.62% in 2026.
- Tracing GYRE's Cash from Operations over 5 years: stood at 42298000.0 in 2022, then tumbled by 92.06% to 3360000.0 in 2023, then plunged by 182.08% to 2758000.0 in 2024, then slumped by 103.05% to 5600000.0 in 2025, then surged by 157.14% to 3200000.0 in 2026.
- Per Business Quant, the three latest GYRE Cash from Operations figures stand at 3200000.0 (Q1 2026), 5600000.0 (Q4 2025), and 4600000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.20 Mn |
| Mar 31, 2026 | 3.20 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 2.13 Mn |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Dec 31, 2024 | -2.76 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | 3.36 Mn |
| Dec 31, 2023 | 3.36 Mn |
| Sep 30, 2023 | 7.58 Mn |
| Sep 30, 2023 | 7.58 Mn |
| Jun 30, 2023 | 4.53 Mn |
| Jun 30, 2023 | 4.53 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Dec 31, 2022 | 42.30 Mn |
| Dec 31, 2022 | 42.30 Mn |
| Sep 30, 2022 | -7.28 Mn |
| Sep 30, 2022 | -7.28 Mn |
| Jun 30, 2022 | -12.29 Mn |
| Jun 30, 2022 | -12.29 Mn |
| Mar 31, 2022 | -12.05 Mn |
| Mar 31, 2022 | -12.05 Mn |
| Dec 31, 2021 | -17.68 Mn |
| Dec 31, 2021 | -17.68 Mn |
| Sep 30, 2021 | -21.60 Mn |
| Sep 30, 2021 | -21.60 Mn |
| Jun 30, 2021 | -20.12 Mn |
| Jun 30, 2021 | -20.12 Mn |
| Mar 31, 2021 | -24.36 Mn |
| Mar 31, 2021 | -24.36 Mn |
| Dec 31, 2020 | -22.11 Mn |
| Dec 31, 2020 | -22.11 Mn |
| Sep 30, 2020 | -13.01 Mn |
| Sep 30, 2020 | -13.01 Mn |
| Jun 30, 2020 | -15.14 Mn |
| Jun 30, 2020 | -15.14 Mn |
| Mar 31, 2020 | -4.79 Mn |
| Mar 31, 2020 | -4.79 Mn |
| Dec 31, 2019 | -8.09 Mn |
| Dec 31, 2019 | -8.09 Mn |
| Sep 30, 2019 | -9.10 Mn |
| Sep 30, 2019 | -9.10 Mn |
| Jun 30, 2019 | -11.47 Mn |
| Jun 30, 2019 | -11.47 Mn |
| Mar 31, 2019 | -14.96 Mn |
| Mar 31, 2019 | -14.96 Mn |
| Dec 31, 2018 | -9.01 Mn |
| Dec 31, 2018 | -9.01 Mn |
| Sep 30, 2018 | -7.02 Mn |
| Sep 30, 2018 | -7.02 Mn |
| Jun 30, 2018 | -7.41 Mn |
| Jun 30, 2018 | -7.41 Mn |
| Mar 31, 2018 | -5.11 Mn |
| Mar 31, 2018 | -5.11 Mn |
| Dec 31, 2017 | -6.32 Mn |
| Dec 31, 2017 | -6.32 Mn |
| Sep 30, 2017 | -4.93 Mn |
| Sep 30, 2017 | -4.93 Mn |
| Jun 30, 2017 | -4.40 Mn |
| Jun 30, 2017 | -4.40 Mn |
| Mar 31, 2017 | -4.29 Mn |
| Mar 31, 2017 | -4.29 Mn |
| Dec 31, 2016 | -4.98 Mn |
| Dec 31, 2016 | -4.98 Mn |
| Sep 30, 2016 | -5.11 Mn |
| Sep 30, 2016 | -5.11 Mn |
| Jun 30, 2016 | -3.64 Mn |
| Jun 30, 2016 | -3.64 Mn |
| Mar 31, 2016 | -4.74 Mn |
| Mar 31, 2016 | -4.74 Mn |
| Dec 31, 2015 | -5.14 Mn |
| Dec 31, 2015 | -5.14 Mn |
| Sep 30, 2015 | -9.63 Mn |
| Sep 30, 2015 | -9.63 Mn |
| Jun 30, 2015 | -1.37 Mn |
| Jun 30, 2015 | -1.37 Mn |
| Mar 31, 2015 | -2.98 Mn |
| Mar 31, 2015 | -2.98 Mn |
| Dec 31, 2014 | -2.06 Mn |
| Dec 31, 2014 | -2.06 Mn |
| Sep 30, 2014 | 19.43 Mn |
| Sep 30, 2014 | 19.43 Mn |
| Jun 30, 2014 | -8.91 Mn |
| Jun 30, 2014 | -8.91 Mn |
| Mar 31, 2014 | -14.85 Mn |
| Mar 31, 2014 | -14.85 Mn |
| Dec 31, 2013 | 23.17 Mn |
| Dec 31, 2013 | 23.17 Mn |
| Sep 30, 2013 | -9.71 Mn |
| Sep 30, 2013 | -9.71 Mn |
| Jun 30, 2013 | -10.42 Mn |
| Jun 30, 2013 | -10.42 Mn |
| Mar 31, 2013 | -9.32 Mn |
| Mar 31, 2013 | -9.32 Mn |
| Dec 31, 2012 | -11.60 Mn |
| Dec 31, 2012 | -11.60 Mn |
| Sep 30, 2012 | -10.40 Mn |
| Sep 30, 2012 | -10.40 Mn |
| Jun 30, 2012 | -17.34 Mn |
| Jun 30, 2012 | -17.34 Mn |
| Mar 31, 2012 | -24.90 Mn |
| Mar 31, 2012 | -24.90 Mn |
| Dec 31, 2011 | -20.53 Mn |
| Dec 31, 2011 | -20.53 Mn |
| Sep 30, 2011 | -18.08 Mn |
| Sep 30, 2011 | -18.08 Mn |
| Jun 30, 2011 | -23.06 Mn |
| Jun 30, 2011 | -23.06 Mn |
| Mar 31, 2011 | -22.05 Mn |
| Mar 31, 2011 | -22.05 Mn |
| Dec 31, 2010 | -15.71 Mn |
| Dec 31, 2010 | -15.71 Mn |
| Sep 30, 2010 | -16.99 Mn |
| Sep 30, 2010 | -16.99 Mn |